Protease activation and glucocorticoid-induced apoptosis in chronic lymphocytic leukemia

David J. McConkey, Joya Chandra

Research output: Contribution to journalReview articlepeer-review

Abstract

Chronic lymphocytic leukemia (CLL) is at present an incurable disease. All of the drugs used in the treatment of CLL induce apoptosis in the cells, and in vitro responses to glucocorticoid or analogs correlate with in vivo sensitivity to these agents. Since CLL lymphocytes accumulate rather than proliferate, the idea that CLL is a disease involving defective apoptosis is particularly attractive. Recent studies have identified many of the central components of the apoptotic pathway that appear to be conserved from one cell type to another. Thus, investigation into the functionality of these molecules should reveal where the defect(s) in apoptosis may lie in CLL cells. Protease activation is a central event during apoptosis, and leads to many of the familiar characteristics of apoptosis. Here we will examine the role of apoptotic proteases in CLL and speculate on their contribution to disease emergence and drug resistance.

Original languageEnglish (US)
Pages (from-to)421-431
Number of pages11
JournalLeukemia and Lymphoma
Volume33
Issue number5-6
DOIs
StatePublished - 1999
Externally publishedYes

Keywords

  • Chronic lymphocytic leukemia
  • Glucocorticoid-induced apoptosis
  • Protease activation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Protease activation and glucocorticoid-induced apoptosis in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this